📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 14:05
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Rs 13.15 Lakh Q1 Profit: Emmessar Biotech Reports 23% YoY Decline in Net Profit
Emmessar Biotech & Nutrition Ltd reported a net profit of Rs 13.15 Lakhs for Q1 FY27 (ended June 30, 2026), down 23.2% from Rs 17.12 Lakhs in the year-ago period. Revenue from operations (Healthcare segment) fell 36% YoY to Rs 5.93 Lakhs. The company remains heavily dependent on 'Rent on Leasehold Land,' which contributed Rs 41.33 Lakhs to segment revenue, significantly more than its core operations. Total expenses rose to Rs 43.55 Lakhs, driven by a 23.7% increase in employee benefit costs.
Confidence: HIGH
What changedThe company released its unaudited financial results for the first quarter of the 2026-27 fiscal year, showing a contraction in both operational revenue and bottom-line profit.
Why it mattersFor a micro-cap company with a market cap of just Rs 12 Cr, the lack of growth in core operations and heavy reliance on rental income suggests a stagnant business model with limited operational leverage.
Net Profit (Q1 FY27): Rs 13.15 LakhsRevenue from Operations (Q1 FY27): Rs 5.93 LakhsRental Income (Segment): Rs 41.33 LakhsEmployee Benefit Expenses: Rs 30.32 LakhsEPS (Basic): Rs 0.26
📅 Short termThe stock is likely to remain range-bound given the small absolute profit figures and the decline in YoY performance.
📈 Long termLimited structural significance unless the company demonstrates a turnaround in its healthcare/biotech operations, which currently contribute minimally to the bottom line.
⚠ Risk flags
- High concentration risk (reliance on rental income)
- Declining operational revenue
- Rising employee costs relative to total income
Key Highlights
Net Profit after tax stood at Rs 13.15 Lakhs vs Rs 17.12 Lakhs in Q1 FY26.
Revenue from operations declined to Rs 5.93 Lakhs from Rs 9.28 Lakhs YoY.
Rental income from leasehold land remained stagnant at Rs 41.33 Lakhs for the quarter.
Employee benefit expenses increased to Rs 30.32 Lakhs from Rs 24.50 Lakhs YoY.
Basic and Diluted EPS decreased to Rs 0.26 from Rs 0.34 YoY.
👀 What to Watch
Investors should monitor if the company can scale its Healthcare segment, as current profitability is almost entirely supported by rental income. The upcoming AGM on September 29, 2026, may provide more clarity on business strategy.
Q1 Net Profit at ₹13.15 Lakhs; Core Healthcare Revenue Declines 36% YoY
Emmessar Biotech reported a weak operational performance for Q1 FY27, with core healthcare revenue falling to ₹5.93 Lakhs from ₹9.28 Lakhs YoY. Total income of ₹59.85 Lakhs was primarily sustained by rental income from leasehold land (₹41.33 Lakhs) and other income. Net profit for the quarter stood at ₹13.15 Lakhs, a 23% decline from ₹17.12 Lakhs in the same quarter last year. The company remains a micro-cap entity with a ₹12 Cr market cap and minimal operational scale in its primary industry.
Confidence: HIGH
What changedThe company released its Q1 FY27 results, showing a continued decline in core operational revenue while maintaining profitability through rental income.
Why it mattersFor a company with a ₹12 Cr market cap, the lack of core business revenue (Healthcare) indicates it is currently functioning more as an asset-holding entity than an active biotech firm.
Revenue from Operations: ₹5.93 LakhsNet Profit: ₹13.15 LakhsRental Income: ₹41.33 LakhsOther Income: ₹53.92 LakhsEPS: ₹0.26Q1 Revenue vs TTM Revenue: 16.02%
📅 Short termThe stock is likely to remain neutral given the low absolute profit figures and lack of operational growth in the core segment.
📈 Long termLimited structural significance unless the company can successfully pivot or scale its healthcare and nutrition business beyond its current negligible levels.
⚠ Risk flags
- High reliance on non-operational rental income
- Negligible core business revenue
- Micro-cap liquidity risk
Key Highlights
Revenue from operations dropped 36% YoY to ₹5.93 Lakhs from ₹9.28 Lakhs.
Rental income from leasehold land contributed ₹41.33 Lakhs, representing 69% of total income.
Net profit for the quarter ended June 2026 was ₹13.15 Lakhs, down from ₹17.12 Lakhs YoY.
Total expenses increased to ₹43.55 Lakhs compared to ₹39.57 Lakhs in the previous year's quarter.
The 34th Annual General Meeting is scheduled for September 29, 2026, via video conferencing.
👀 What to Watch
Monitor management commentary during the upcoming AGM on September 29 regarding the strategy to scale the healthcare segment, as the current business is primarily driven by rental income.
